After 90 days of follow‐up, it was found that patients with poor prognosis had much higher serum levels of RIPK1 and RIPK3 than those with good prognosis, suggesting that the increase of serum RIPK1 and RIPK3 levels may increase the risk of poor prognosis in AIS patients. This evidence concerns the gene RIPK1 and androgen insensitivity syndrome.